"Daiichi Sankyo Co (4568.T), Japan's third-largest drugmaker, said it plans to apply by March 2010 for marketing approval in Japan of an influenza drug candidate, and seek approval in Taiwan, Hong Kong and South Korea soon afterwards."
""Prompted by rapidly increasingly needs for new influenza treatment, we have sped up the development of the drug and are now set to complete all our six lines of clinical tests, three for use in adults and three for children, by March," said Daiichi Sankyo director Daisuke Hiro."
